Researchers have halted a study of Gilead Sciences’ emtricitabine tenofovir (Truvada) after it failed to show in a study that it can help prevent HIV infections among women in Africa, according to a report from the Associated Press. The finding was disappointing, the AP notes, because a previous study showed that the drug from Foster City, CA-based Gilead (NASDAQ: [[ticker:GILD]]) was able to prevent HIV infections in gay and bisexual men when it was given with condoms, counseling, and other prevention services.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
